8-K: TG Therapeutics Q1 2026 Earnings Beat, Revenue Guidance Raised

TG Therapeutics reported strong first quarter 2026 results, exceeding expectations with significant BRIUMVI revenue and raising full-year financial guidance.

Summary

• TG Therapeutics reported first quarter 2026 total global revenue of approximately $205 million.
• BRIUMVI U.S. net product revenue for Q1 2026 was approximately $195 million, showing a 63% increase year-over-year.
• The company raised its full-year 2026 total global revenue target to approximately $925 million.
• Full-year 2026 BRIUMVI U.S. net product revenue guidance was increased to $885-$900 million.
• Net income for Q1 2026 was $19.8 million, a significant increase from $5.1 million in Q1 2025.
• Cash, cash equivalents, and investment securities stood at $572.8 million as of March 31, 2026.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive report, driven by significantly better-than-expected BRIUMVI sales and a substantial increase in full-year revenue guidance, alongside securing additional capital.

Positives

• BRIUMVI U.S. net product revenue of $194.8 million in Q1 2026, a 63% quarterly growth over the prior year.
• Raised full-year 2026 total global revenue guidance to approximately $925 million.
• Increased full-year 2026 BRIUMVI U.S. net product revenue target to $885-$900 million.
• Provided a Q2 2026 BRIUMVI U.S. net product revenue target of approximately $220 million.
• Net income for Q1 2026 was $19.8 million, up from $5.1 million in Q1 2025.
• Secured an additional $500 million in non-dilutive capital from Blue Owl Capital.
• Expanded share repurchase program from $100 million to $300 million, with $200 million remaining.
• Completed $100 million in share repurchases during Q1 2026.

Negatives

• R&D expenses increased to $48.4 million in Q1 2026 from $46.4 million in Q1 2025, primarily due to license/milestone expenses and clinical trial costs.
• SG&A expenses significantly increased to $88.2 million in Q1 2026 from $50.3 million in Q1 2025, driven by increased marketing and personnel costs for BRIUMVI commercialization.
• Interest expense increased to $7.7 million in Q1 2026 from $6.8 million in Q1 2025.
• Loss on extinguishment of debt was $9.2 million in Q1 2026.

Risks

• Potential for infusion reactions, serious infections, and HBV reactivation in patients treated with BRIUMVI.
• Risk of Progressive Multifocal Leukoencephalopathy (PML) in immunocompromised patients treated with anti-CD20 antibodies.
• Potential for fetal harm and transient B-cell depletion in infants born to mothers treated with BRIUMVI during pregnancy.
• Risk of reduction in immunoglobulin levels, particularly IgM, which could lead to opportunistic or recurrent infections.
• Possibility of clinically significant liver injury in patients treated with BRIUMVI.
• The company faces risks related to the continued commercialization of BRIUMVI, including maintaining prescription trends and payor coverage.
• Uncertainty regarding the success and regulatory approval of subcutaneous BRIUMVI and the ENHANCE Phase 3 trial.
• Potential delays in clinical trial data readouts due to enrollment, data collection, or maturity.

Future Outlook

The company raised its full-year 2026 total global revenue target to approximately $925 million and increased the BRIUMVI U.S. net product revenue target to $885-$900 million. A second quarter 2026 BRIUMVI U.S. net product revenue target of approximately $220 million was provided. Full-year 2026 operating expenses are projected at approximately $350 million, excluding non-cash compensation, plus approximately $100 million for subcutaneous BRIUMVI manufacturing and start-up costs.

Management Comments

• "We are off to a strong start in 2026, with BRIUMVI performance exceeding expectations and momentum continuing to build."
• "Growth is being driven by strong underlying demand, record new patient starts, and consistent commercial execution reinforcing our belief that we remain early in the adoption curve for BRIUMVI."
• "Based on this performance, we are significantly increasing our full-year U.S. BRIUMVI revenue guidance to $885-900 million and continue to see the brand as having a multi-billion-dollar potential before considering the impact of a subcutaneous BRIUMVI currently under development."
• "With multiple near-term clinical catalysts and ongoing efforts to expand the franchise, we believe BRIUMVI is well-positioned to become a leading therapy in MS and a durable, long-term growth driver for TG."

Industry Context

StockSavvy.ai notes that TG Therapeutics' strong Q1 performance and raised guidance for BRIUMVI reflect positive market adoption in the competitive Multiple Sclerosis (MS) therapeutic landscape, where other companies are also advancing their B-cell targeting therapies.

Comparison to Industry Standards

• No direct comparisons to specific industry benchmarks or competitor results were provided in the filing.
• The filing highlights BRIUMVI's performance against its own prior guidance and historical performance, indicating significant growth.
• The company's stated belief in BRIUMVI's multi-billion-dollar potential suggests an ambition to compete with established blockbuster MS therapies.

Stakeholder Impact

• Shareholders: Positive impact due to increased revenue guidance, strong sales performance, and capital infusion, potentially leading to stock price appreciation.
• Employees: Continued commercialization efforts and pipeline development may lead to job growth and opportunities.
• Customers (Patients): Continued access to BRIUMVI for Relapsing Multiple Sclerosis (RMS) treatment, with ongoing research into new formulations and indications.
• Suppliers/Partners: Increased demand for BRIUMVI may lead to higher volumes for manufacturing and distribution partners.

Next Steps

• Announce topline Phase 3 data for ENHANCE trial combining Day 1 and Day 15 doses of IV BRIUMVI mid-year 2026.
• Present preliminary Phase 1 azer-cel data in Progressive MS in the second half of 2026.
• Announce topline Phase 3 data for subcutaneous BRIUMVI (ublituximab) year-end 2026/first quarter 2027.
• Commence a potentially registration-directed trial for BRIUMVI in Myasthenia Gravis (MG).
• Commence additional exploratory studies for BRIUMVI and azer-cel in autoimmune disease (outside MS).

Key Dates

Recommendation

The company has demonstrated exceptional execution with BRIUMVI, significantly exceeding revenue expectations and raising full-year guidance. The strong cash position, successful capital raise, and active share repurchase program, combined with a robust pipeline and upcoming clinical catalysts, present a compelling investment case for substantial future growth.

Keywords

TG Therapeutics, BRIUMVI, Multiple Sclerosis, Q1 2026 Earnings, Revenue Guidance, Biotechnology, Pharmaceuticals, Clinical Trials